Are Peptides Safe? What Research Evidence Can and Cannot Show

“Are peptides safe?” sounds like a yes-or-no question, but safety is not a property a substance simply has — it is a conclusion that depends on evidence, dose, route, formulation and population. This article explains what different kinds of evidence can and cannot show, and why none of them is a purity percentage.

This is educational information about evidence, not health advice. FirstLabs materials are for laboratory research only, not human consumption, and this site does not provide dosing or personal-use guidance.

The evidence ladder

Different study types answer different questions. Cell and biochemical studies explore mechanisms. Animal studies test whether a mechanism survives contact with a living system — in that species, at those doses. Human clinical trials measure safety and efficacy in a defined population, with a defined formulation, under medical monitoring.

A finding only travels as far as its design allows. A result in isolated mitochondria or in mice cannot be carried over to people, and a result from a clinical trial applies to the studied formulation — not to a retail research vial that shares a name with the study drug.

Why purity is not safety

A certificate of analysis reporting 99% purity describes an analytical measurement: how much of the target compound a method detected in a sample. It does not measure biological activity, toxicity or sterility, and it cannot find contaminants the method was not designed to detect. Our purity-versus-quantity guide explains what these measurements actually capture.

Safety questions are answered by toxicology and clinical evidence, not chromatography. A high purity number on an unauthorized product is still a number about an unauthorized product.

What the regulator says

Health Canada warns that unauthorized injectable peptide drugs sold online can pose serious health risks — including infection, allergic reactions and interactions with other medications — and that they have not been assessed for safety, efficacy or quality. Its 2026 public warning lists seized products including BPC-157, GHK-Cu, Ipamorelin, KPV, SS-31, TB-500 and Retatrutide, and advises that authorized drugs carry an eight-digit DIN and come through licensed pharmacies.

A practical way to read safety claims

• Ask what kind of evidence is behind a claim: mechanism, animal data, human trial, or anecdote.
• Check whether the studied material matches what is being sold — formulation, not just name.
• Treat testimonials and before-and-after photos as marketing, not evidence.
• Remember that “research use only” means the human safety profile is not established.
• Bring health questions to a licensed healthcare professional, not to a seller or a forum.

For evaluating the documents behind any specific material, use the COA verification checklist and the Canadian research guide library.

Source and scope

Health Canada (2026): Think twice before injecting peptides bought online — the regulator's public warning on unauthorized injectable peptide drugs, cited for the risk summary above.

The cover is an illustrative laboratory image, not a FirstLabs facility photograph or study result. Educational information only; not medical advice.